Found 26 Multiple Myeloma trials
A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 29420: Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects With Relapsed or Refractory Multiple Myeloma
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.
Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide
We are doing this study to see if CAR T-cell therapy (bb2121) and maintenance therapy with the drug lenalidomide can help delay multiple myeloma from coming back.
UPCC 04423: Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and an Anti-CD38 Antibody
Compassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma. We would like to rely on WCG as the IRB of record for this study.
UPCC 14419: A Phase 1 First in Human Study Evaluating the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose escalation study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory AML.
Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
Participants invited to participate in a research study must have diagnosis of multiple myeloma and have been previously treated with the study drug, cilta-cel. The purpose of this research is to monitor the health status of subjects who were previously enrolled in cilta-cel.
UPCC 07419: A Phase 1b/2a Multicenter Open-Label Dose Escalation Study to Determine the Maximum Tolerated Dose Assess the Safety Tolerability Pharmacokinetics and Efficacy Of Cc-220 Monotherapy and In Combination With Other Treatments In Subjects With Relapsed and Refractory Multiple Myeloma
The purpose of this study is to test the safety of an experimental drug CC-220, alone and in combination with other treatments. The study is also designed to define the appropriate dose for further testing of the study drug and these experimental combinations.
Please choose between Voice or SMS based delivery of verification code
or